APA (7th ed.) Citation

Tanaka, A., Shibata, H., Imai, T., Yoshida, H., Miyazono, M., Takahashi, N., . . . Node, K. (2023). Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR). Cardiovascular diabetology, 22(1), 194-11. https://doi.org/10.1186/s12933-023-01928-y

Chicago Style (17th ed.) Citation

Tanaka, Atsushi, et al. "Rationale and Design of an Investigator-initiated, Multicenter, Prospective, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR)." Cardiovascular Diabetology 22, no. 1 (2023): 194-11. https://doi.org/10.1186/s12933-023-01928-y.

MLA (9th ed.) Citation

Tanaka, Atsushi, et al. "Rationale and Design of an Investigator-initiated, Multicenter, Prospective, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR)." Cardiovascular Diabetology, vol. 22, no. 1, 2023, pp. 194-11, https://doi.org/10.1186/s12933-023-01928-y.